IR@PKUHSC  > 北京大学临床肿瘤学院  > 乳腺癌预防治疗中心
学科主题临床医学
Prevalence of BRCA1 mutations and responses to neoadjuvant chemotherapy among BRCA1 carriers and non-carriers with triple-negative breast cancer
Wang, C.; Zhang, J.; Wang, Y.; Ouyang, T.; Li, J.; Wang, T.; Fan, Z.; Fan, T.; Lin, B.; Xie, Y.
关键词BRCA1 mutations triple-negative breast cancer neoadjuvant chemotherapy
刊名ANNALS OF ONCOLOGY
2015-03-01
DOI10.1093/annonc/mdu559
26期:3页:523-528
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
研究领域[WOS]Oncology
关键词[WOS]PATHOLOGICAL COMPLETE RESPONSE ; YOUNG-WOMEN ; POPULATION ; SURVIVAL ; THERAPY
英文摘要

Background: The frequency of BRCA1 germline mutations among Chinese women with triple-negative breast cancer is unclear, and the association between BRCA1 mutations and the response to neoadjuvant chemotherapy in women with triple-negative breast cancer has not been determined.

Patients and methods: Nine hundred and fifty-six triple-negative breast cancer patients were treated at our institute between 2003 and 2012; we tested the BRCA1/2 mutations for 956 patients and 953 patients in this cohort, respectively. Among the 956patients, 652 patients received neoadjuvant chemotherapy.

Results: In this cohort, 7.1% (68/956) and 2.3% (22/953) of patients carried a BRCA1 or BRCA2 mutation, respectively. The BRCA1/2 mutation rates were 10.5% and 3.0% among the patients who were diagnosed at or before the age of 50 in this cohort, respectively. The pCR (pathologic complete response) rate was 31.6% in the 652 patients who received neoadjuvant chemotherapy. BRCA1 carriers had a significantly higher pCR rate than non-carriers (BRCA1 carriers versus non-carriers, 53.8% versus 29.7%, P < 0.001). Among women treated with anthracycline with or without taxane regimens, the pCR rate was 57.1% for BRCA1 carriers, 29.0% for non-carriers (P < 0.001); among women treated with taxane regimens, the pCR rate was 40.0% for BRCA1 carriers, 32.9% for non-carriers (P = 0.73). At a median follow-up of 43 months, the recurrence-free survival was similar between BRCA1 carriers and non-carriers among the 947 patients of this study (adjusted hazard ratio = 0.92; 95% confidence interval: 0.45-1.90; P = 0.82).

Conclusions: Chinese women with triple-negative breast cancer who are diagnosed at or before age of 50 are candidates for BRCA1 genetic testing. Among triple-negative breast cancer patients, BRCA1 carriers are more likely to respond to neoadjuvant anthracycline-based regimens than are non-carriers.

语种英语
WOS记录号WOS:000352228700011
Citation statistics
Cited Times:16[WOS]   [WOS Record]     [Related Records in WOS]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/60725
Collection北京大学临床肿瘤学院_乳腺癌预防治疗中心
作者单位Peking Univ, Canc Hosp & Inst, Breast Ctr, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China
Recommended Citation
GB/T 7714
Wang, C.,Zhang, J.,Wang, Y.,et al. Prevalence of BRCA1 mutations and responses to neoadjuvant chemotherapy among BRCA1 carriers and non-carriers with triple-negative breast cancer[J]. ANNALS OF ONCOLOGY,2015,26(3):523-528.
APA Wang, C..,Zhang, J..,Wang, Y..,Ouyang, T..,Li, J..,...&Xie, Y..(2015).Prevalence of BRCA1 mutations and responses to neoadjuvant chemotherapy among BRCA1 carriers and non-carriers with triple-negative breast cancer.ANNALS OF ONCOLOGY,26(3),523-528.
MLA Wang, C.,et al."Prevalence of BRCA1 mutations and responses to neoadjuvant chemotherapy among BRCA1 carriers and non-carriers with triple-negative breast cancer".ANNALS OF ONCOLOGY 26.3(2015):523-528.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
谷歌学术
谷歌学术Similar articles in
[Wang, C.]'s Articles
[Zhang, J.]'s Articles
[Wang, Y.]'s Articles
百度学术
百度学术Similar articles in
[Wang, C.]'s Articles
[Zhang, J.]'s Articles
[Wang, Y.]'s Articles
必应学术
必应学术Similar articles in
[Wang, C.]'s Articles
[Zhang, J.]'s Articles
[Wang, Y.]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.